Floatz logo

METRONIDAZOLE

For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method

Liaoning Cancer Hospital & InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method cohort.

Asset / SponsorPhaseRating
Binimetinib
Pierre Fabre Medicament
Phase 3BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Inno-206
Northwell Health
Phase 4B
Durvalumab
University of Iowa
Phase 2B

View all 50 →

Same molecule, other indications

METRONIDAZOLE is also rated in:

Surgical Site InfectionDormant
BBB
Indicative ·
72 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
Surgery--ComplicationsDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →